Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at ruxolitinib before a stem cell transplant for myelofibrosis (MPD-RC114)
This trial looked at ruxolitinib before a stem cell transplant to improve treatment for people with myelofibrosis.
Myelofibrosis is a rare blood disorder. It is a condition that causes scarring of the
This trial was open for people to join between 2015 and 2017. These results were published in 2018.
More about this trial
- find out if having ruxolitinib before a stem cell transplant improved treatment
- learn more about the side effects
Summary of results
- 5 had a transplant from a family member (related donor)
- 14 had a transplant from outside the family (an unrelated donor)
The study closed earlier than planned. This was because:
- it was difficult to find enough people to join
- treatment wasn’t working as well as researchers had hoped
- a drop in the number of red blood cells (anaemia)
- an increased risk of bleeding
- within 100 days of having a transplant, 12 people had developed short term graft versus host disease
- after 100 days, 11 had long term graft versus host disease
How to join a clinical trial
Dr Adam Mead
NIHR Clinical Research Network: Cancer
Oxford University Hospitals NHS Trust